Literature DB >> 15543532

Inhibition of allogeneic T-cell responses by dendritic cells expressing transduced indoleamine 2,3-dioxygenase.

Naoko Funeshima1, Masayuki Fujino, Yusuke Kitazawa, Yuko Hara, Yoshiaki Hara, Kou Hayakawa, Torayuki Okuyama, Hiromitus Kimura, Xiao-Kang Li.   

Abstract

BACKGROUND: Indoleamine 2,3-dioxygenase (IDO) is an enzyme involved in the catabolism of tryptophan and has been shown to prevent rejection of the fetus during pregnancy by inhibiting alloreactive T cells.
METHODS: In this study we investigated dendritic cells (DCs) that are transfected with IDO cDNA in the inhibition of T-cell proliferation after antigen-specific interaction. XS106 DCs, derived from A/J mice (H-2k), were transduced with IDO with a gene-delivery system using a recombinant adenoviral vector.
RESULTS: Western blotting and immune staining revealed IDO expression in XS106 DCs transduced with IDO (XS106-IDO DCs), and its catabolic effect was confirmed by an increase in kynurenine concentration. Fluorescence-activated cell sorting revealed that XS106-IDO DCs were not changeable for Ia, CD80, and CD86 expression. After XS106-IDO DCs were co-cultured with C57BL/6 allogeneic splenic T cells, the proliferation of the T cell was significantly inhibited. The co-cultured T cells with XS106-IDO DCs exhibited cell-cycle arrest. Furthermore, injection of XS160-IDO DCs into the footpads of C57BL/6 (H-2b) mice demonstrated a reduced T-cell response against allo-antigen.
CONCLUSIONS: These results suggest that overexpression of IDO in the DCs effectively inhibited T-cell proliferation, and may expand a new immunomodulatory strategy for the prevention of allo-rejection of organ transplantation. Copyright (c) 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15543532     DOI: 10.1002/jgm.698

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  11 in total

Review 1.  Advancements in immune tolerance.

Authors:  Ping-Ying Pan; Junko Ozao; Zuping Zhou; Shu-Hsia Chen
Journal:  Adv Drug Deliv Rev       Date:  2007-10-05       Impact factor: 15.470

Review 2.  Is the CD200/CD200 receptor interaction more than just a myeloid cell inhibitory signal?

Authors:  Konstantinos Minas; Janet Liversidge
Journal:  Crit Rev Immunol       Date:  2006       Impact factor: 2.214

3.  Inhibition of allogeneic T-cell response by Kupffer cells expressing indoleamine 2,3-dioxygenase.

Authors:  Mao-Lin Yan; Yao-Dong Wang; Yi-Feng Tian; Zhi-De Lai; Lv-Nan Yan
Journal:  World J Gastroenterol       Date:  2010-02-07       Impact factor: 5.742

4.  Revisiting the Principles of Designing a Vaccine.

Authors:  Shubhranshu Zutshi; Sunil Kumar; Prashant Chauhan; Bhaskar Saha
Journal:  Methods Mol Biol       Date:  2022

Review 5.  IDO: a double-edged sword for T(H)1/T(H)2 regulation.

Authors:  Hui Xu; Guang-Xian Zhang; Bogoljub Ciric; Abdolmohamad Rostami
Journal:  Immunol Lett       Date:  2008-09-29       Impact factor: 3.685

6.  Dendritic Cells Treated with Exogenous Indoleamine 2,3-Dioxygenase Maintain an Immature Phenotype and Suppress Antigen-specific T cell Proliferation.

Authors:  Evelyn Bracho-Sanchez; Azadeh Hassanzadeh; Maigan A Brusko; Mark A Wallet; Benjamin G Keselowsky
Journal:  J Immunol Regen Med       Date:  2019-02-10

7.  Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma.

Authors:  Jin Ye; Hui Liu; Yanming Hu; Peng Li; Gehua Zhang; Yuan Li
Journal:  Virchows Arch       Date:  2012-11-20       Impact factor: 4.064

8.  Indoleamine 2,3-dioxygenase tissue distribution and cellular localization in mice: implications for its biological functions.

Authors:  Xiangchen Dai; Bao Ting Zhu
Journal:  J Histochem Cytochem       Date:  2009-09-09       Impact factor: 2.479

9.  Plant microRNAs as novel immunomodulatory agents.

Authors:  Duccio Cavalieri; Lisa Rizzetto; Noemi Tocci; Damariz Rivero; Elisa Asquini; Azeddine Si-Ammour; Elena Bonechi; Clara Ballerini; Roberto Viola
Journal:  Sci Rep       Date:  2016-05-11       Impact factor: 4.379

10.  Exosomes derived from atorvastatin-modified bone marrow dendritic cells ameliorate experimental autoimmune myasthenia gravis by up-regulated levels of IDO/Treg and partly dependent on FasL/Fas pathway.

Authors:  Xiao-Li Li; Heng Li; Min Zhang; Hua Xu; Long-Tao Yue; Xin-Xin Zhang; Shan Wang; Cong-Cong Wang; Yan-Bin Li; Ying-Chun Dou; Rui-Sheng Duan
Journal:  J Neuroinflammation       Date:  2016-01-12       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.